ELIXA

What is ELIXA?

Cardiovascular safety for lixisenatide after acute coronary syndrome in type 2 diabetes (Pfeffer et al., NEJM 2015): noninferior for MACE, not superior.

The first GLP-1 cardiovascular outcomes trial completed under the FDA's post-2008 CV-safety guidance.

Related reading: ELIXA: The First One, and It Was Neutral

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where ELIXA comes up on this site

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers